Tag Archives: Alethia Young

Alnylam Pharma Receives a Hold from Credit Suisse

In a report released yesterday, Alethia Young from Credit Suisse maintained a Hold rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $50. The company’s shares closed yesterday at $52.61. According to TipRanks.com, Young is a 2-star analyst

Regeneron Gets a Buy Rating from Credit Suisse

In a report released yesterday, Alethia Young from Credit Suisse maintained a Buy rating on Regeneron (NASDAQ: REGN), with a price target of $485. The company’s shares closed yesterday at $429. According to TipRanks.com, Young is a 3-star analyst with

Credit Suisse Issues a Buy Rating on Coherus Biosciences

Credit Suisse analyst Alethia Young maintained a Buy rating on Coherus Biosciences (NASDAQ: CHRS) on April 19 and set a price target of $38. The company’s shares closed yesterday at $18.75. According to TipRanks.com, Young is a 1-star analyst with

Credit Suisse Issues a Hold Rating on Amgen Inc

Credit Suisse analyst Alethia Young maintained a Hold rating on Amgen Inc (NASDAQ: AMGN) yesterday and set a price target of $178. The company’s shares opened today at $163.78. According to TipRanks.com, Young is a 2-star analyst with an average

Vertex Pharmaceuticals was Downgraded to a Hold Rating at Credit Suisse

Vertex Pharmaceuticals (NASDAQ: VRTX) received a Hold rating and a $108 price target from Credit Suisse analyst Alethia Young yesterday. The company’s shares opened today at $107.24. According to TipRanks.com, Young is a 2-star analyst with an average return of

Analysts’ Top Healthcare Picks: CHRS, ACRS

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coherus Biosciences (NASDAQ: CHRS) and Aclaris Therapeutics Inc (NASDAQ: ACRS) with bullish sentiments. Coherus Biosciences (NASDAQ: CHRS) In a report released yesterday,